Go offline with the Player FM app!
Is There Anything GLP-1s Can’t Do?
Manage episode 520265907 series 2529451
Weight loss and diabetes drugs in the class called GLP-1s have exploded onto the market, starting to put a real dent in the obesity epidemic. And as doctors are gathering more data, it looks like the medications may also provide real benefits for cardiac health, liver disease, kidney function and possibly even addiction and sleep disorders. In this episode, a panel of experts explains how the drugs work, why they’ve been so effective, and how hopeful we might be about other uses. Cedars Sinai cardiologist Martha Gulati joins Nora Volkow, the director of the National Institute on Drug Abuse and Diana Thiara, an obesity expert at UCSF, for a forward-looking conversation about this potentially game-changing medical advancement. Time Magazine health reporter Alice Park moderates the conversation.
573 episodes
Manage episode 520265907 series 2529451
Weight loss and diabetes drugs in the class called GLP-1s have exploded onto the market, starting to put a real dent in the obesity epidemic. And as doctors are gathering more data, it looks like the medications may also provide real benefits for cardiac health, liver disease, kidney function and possibly even addiction and sleep disorders. In this episode, a panel of experts explains how the drugs work, why they’ve been so effective, and how hopeful we might be about other uses. Cedars Sinai cardiologist Martha Gulati joins Nora Volkow, the director of the National Institute on Drug Abuse and Diana Thiara, an obesity expert at UCSF, for a forward-looking conversation about this potentially game-changing medical advancement. Time Magazine health reporter Alice Park moderates the conversation.
573 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.